Japanese Journal of Ophthalmology

, Volume 56, Issue 5, pp 497–501

Effectiveness of 1.25 % povidone–iodine combined with topical levofloxacin against conjunctival flora in intravitreal injection

  • Yasushi Ikuno
  • Miki Sawa
  • Motokazu Tsujikawa
  • Fumi Gomi
  • Naoyuki Maeda
  • Kohji Nishida
Clinical Investigation



To compare the effect of a reduced concentration (1.25 %) of povidone–iodine (PI) eye drops, combined with 0.5 % topical levofloxacin (LVFX), with that of the standard of care (5 % PI) on conjunctival flora before intravitreal injections (IVT).


A prospective, randomized, single-blind clinical trial. One hundred eyes from 100 patients who underwent IVT were included. Eyes were randomly assigned to two groups and underwent different preparatory procedures before therapeutic IVT. LVFX drops were instilled three times every 5 min and then either 1.25 % PI drops were instilled three times every few minutes in group A or 5 % PI drops were instilled three times every few minutes in group B, the control. Conjunctival flora and the injection needles were collected for culture both before and after preparation. The number of positive cultures, the species isolated, and the minimum inhibitory concentrations (MIC) of the antibiotics were assessed.


The pretreatment culture was positive for 45 eyes (86.5 %) in group A (n = 52) and for 37 eyes (77.1 %) in group B (n = 48). After the preparatory procedure, the cultures were positive for 25 eyes (48.1 %) in group A and for 27 eyes (56.3 %) in group B (P = 0.43). After preparation, the number of positive cultures decreased by 46.7 % in group A and by 33.4 % in group B (P = 0.48). No needle samples were contaminated in either group. The most common isolate in both groups after preparation for surgery was Propionibacterium acnes. Among the different antibiotics, vancomycin and oxacillin had the lowest MIC >90 for overall isolates.


1.25 % PI with LVFX is as effective as 5 % PI. P. acnes was the most common conjunctival flora detected. Vancomycin has been confirmed as the best choice for treating infectious endophthalmitis after IVT.


Intravitreal injection Levofloxacin Endophthalmitis Povidine iodine 


  1. 1.
    Bressler NM. Antiangiogenic approaches to age-related macular degeneration today. Ophthalmology. 2009;116:S15–23.PubMedCrossRefGoogle Scholar
  2. 2.
    Ciulla TA, Rosenfeld PJ. Anti-vascular endothelial growth factor therapy for neovascular ocular diseases other than age-related macular degeneration. Curr Opin Ophthalmol. 2009;20:166–74.PubMedCrossRefGoogle Scholar
  3. 3.
    Nicholson BP, Schachat AP. A review of clinical trials of anti-VEGF agents for diabetic retinopathy. Graefes Arch Clin Exp Ophthalmol. 2010;248:915–30.PubMedCrossRefGoogle Scholar
  4. 4.
    Cunningham ET Jr, Adamis AP, Altaweel M, Aiello LP, Bressler NM, D’Amico DJ, et al. Macugen Diabetic Retinopathy Study Group. A phase II randomized double-masked trial of pegaptanib, an anti-vascular endothelial growth factor aptamer, for diabetic macular edema. Ophthalmology. 2005;112:1747–57.PubMedCrossRefGoogle Scholar
  5. 5.
    Cohen SY. Anti-VEGF drugs as the 2009 first-line therapy for choroidal neovascularization in pathologic myopia. Retina. 2009;29:1062–6.PubMedCrossRefGoogle Scholar
  6. 6.
    Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006;355:1419–31.PubMedCrossRefGoogle Scholar
  7. 7.
    Brown DM, Michels M, Kaiser PK, Heier JS, Sy JP, Ianchulev T, et al. Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: two-year results of the ANCHOR study. Ophthalmology. 2009;116:57–65.PubMedCrossRefGoogle Scholar
  8. 8.
    Brown DM, Kaiser PK, Michels M, Soubrane G, Heier JS, Kim RY, et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med. 2006;355:1432–44.PubMedCrossRefGoogle Scholar
  9. 9.
    Kaiser PK, Brown DM, Zhang K, Hudson HL, Holz FG, Shapiro H, et al. Ranibizumab for predominantly classic neovascular age-related macular degeneration: subgroup analysis of first-year ANCHOR results. Am J Ophthalmol. 2007;144:850–7.PubMedCrossRefGoogle Scholar
  10. 10.
    Mason JO 3rd, White MF, Feist RM, Thomley ML, Albert MA, Persaud TO, et al. Incidence of acute onset endophthalmitis following intravitreal bevacizumab (Avastin) injection. Retina. 2008;28:564–7.PubMedCrossRefGoogle Scholar
  11. 11.
    Pilli S, Kotsolis A, Spaide RF, Slakter J, Freund KB, Sorenson J, et al. Endophthalmitis associated with intravitreal anti-vascular endothelial growth factor therapy injections in an office setting. Am J Ophthalmol. 2008;145:879–82.PubMedCrossRefGoogle Scholar
  12. 12.
    Barry P, Gardner S, Seal D, Gettinby G, Lees F, Peterson M, et al. Clinical observations associated with proven and unproven cases in the ESCRS study of prophylaxis of postoperative endophthalmitis after cataract surgery. J Cataract Refract Surg. 2009;35:1523–31.PubMedCrossRefGoogle Scholar
  13. 13.
    Moss JM, Sanislo SR, Ta CN. A prospective randomized evaluation of topical gatifloxacin on conjunctival flora in patients undergoing intravitreal injections. Ophthalmology. 2009;116:1498–501.PubMedCrossRefGoogle Scholar
  14. 14.
    Ziemssen F, Bartz-Schmidt KU. Topical antibiotics to reduce the risk of endophthalmitis after intravitreal injection? Arch Ophthalmol. 2010;128:1222–3.PubMedCrossRefGoogle Scholar
  15. 15.
    Matsumoto M, Suzuma K, Miyamura N, Imamura N, Kitaoka T. Conjunctival swabs and corneoscleral rim cultures from corneal transplantation donors as possible early indicators for posttransplant endopthalmitis. Jpn J Ophthalmol. 2011;55:321–6.PubMedCrossRefGoogle Scholar
  16. 16.
    Speaker MG, Menikoff JA. Prophylaxis of endophthalmitis with topical povidone–iodine. Ophthalmology. 1991;98:1769–75.PubMedGoogle Scholar
  17. 17.
    Ciulla TA, Starr MB, Masket S. Bacterial endophthalmitis prophylaxis for cataract surgery: an evidence-based update. Ophthalmology. 2002;109:13–24. (review).PubMedCrossRefGoogle Scholar
  18. 18.
    Ta CN. Minimizing the risk of endophthalmitis following intravitreous injections. Retina. 2004;24:699–705. (review).PubMedCrossRefGoogle Scholar
  19. 19.
    Berkelman RL, Holland BW, Anderson RL. Increased bacterial activity of dilute preparations of povidone–iodine solutions. J Clin Microbiol. 1982;15:635–9.PubMedGoogle Scholar
  20. 20.
    Shimada H, Arai S, Nakashizuka H, Hattori T, Yuzawa M. Reduction of anterior chamber contamination rate after cataract surgery by intraoperative surface irrigation with 0.25 % povidone–iodine. Ophthalmology. 2011;151:11–7.Google Scholar
  21. 21.
    Isenberg SJ, Apt L, Yoshimori R, Khwarg S. Chemical preparation of the eye in ophthalmic surgery. IV. Comparison of povidone–iodine on the conjunctiva with a prophylactic antibiotic. Arch Ophthalmol. 1985;103:1340–2.PubMedCrossRefGoogle Scholar
  22. 22.
    Inoue Y, Usui M, Ohashi Y, Shiota H, Yamazaki T, Preoperative Disinfection Study Group. Preoperative disinfection of the conjunctival sac with antibiotics and iodine compounds: a prospective randomized multicenter study. Jpn J Ophthalmol. 2008;52:151–61.PubMedCrossRefGoogle Scholar
  23. 23.
    Lemley CA, Han DP. Endophthalmitis: a review of current evaluation and management. Retina. 2007;27:662–80.PubMedCrossRefGoogle Scholar
  24. 24.
    de Caro JJ, Ta CN, Ho HK, Cabael L, Hu N, Sanislo SR, et al. Bacterial contamination of ocular surface and needles in patients undergoing intravitreal injections. Retina. 2008;28:877–83.PubMedCrossRefGoogle Scholar
  25. 25.
    Nentwich M, Yactayo-Miranda Y, Weimann S, Froehlich S, Wolf A, Kampik A, et al. Bacterial contamination of needle points after intravitreal injection. Eur J Ophthalmol. 2009;19:268–72.PubMedGoogle Scholar

Copyright information

© Japanese Ophthalmological Society 2012

Authors and Affiliations

  • Yasushi Ikuno
    • 1
  • Miki Sawa
    • 1
  • Motokazu Tsujikawa
    • 1
  • Fumi Gomi
    • 1
  • Naoyuki Maeda
    • 1
  • Kohji Nishida
    • 1
  1. 1.Department of Ophthalmology E7Osaka University Graduate School of MedicineSuitaJapan

Personalised recommendations